{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:09:50Z","timestamp":1791227390791,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["19K18693"],"award-info":[{"award-number":["19K18693"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["19H01147"],"award-info":[{"award-number":["19H01147"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007325","name":"Kobayashi International Scholarship Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Most patients with ovarian cancer experience recurrence and develop resistance to platinum-based agents. The diagnosis of platinum resistance based on the platinum-free interval is not always accurate and timely in clinical settings. Herein, we used laser ablation inductively coupled plasma mass spectrometry to visualize the platinum distribution in the ovarian cancer tissues at the time of interval debulking surgery after neoadjuvant chemotherapy in 27patients with advanced high-grade serous ovarian cancer. Two distinct patterns of platinum distribution were observed. Type A (n\u2009=\u200916): platinum accumulation at the adjacent stroma but little in the tumor; type B (n\u2009=\u200911): even distribution of platinum throughout the tumor and adjacent stroma. The type A patients treated post-surgery with platinum-based adjuvant chemotherapy showed significantly shorter periods of recurrence after the last platinum-based chemotherapy session (p\u2009=\u20090.020) and were diagnosed with \u201cplatinum-resistant recurrence\u201d. Moreover, type A was significantly correlated with worse prognosis (p\u2009=\u20090.031). Post-surgery treatment with non-platinum-based chemotherapy could be effective for the patients classified as type A. Our findings indicate that the platinum resistance can be predicted prior to recurrence, based on the platinum distribution; this could contribute to the selection of more appropriate adjuvant chemotherapy, which may lead to improves prognoses.<\/jats:p>","DOI":"10.1038\/s41598-022-08503-7","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T09:03:10Z","timestamp":1647421390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Kaname","family":"Uno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Ohnuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Kitami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Iyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Mogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Koya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Kikkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"8503_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s0020-7292(06)60033-7","volume":"95","author":"APM Heintz","year":"2006","unstructured":"Heintz, A. P. M. et al. Carcinoma of the ovary. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet. 95, 161\u2013192. https:\/\/doi.org\/10.1016\/s0020-7292(06)60033-7 (2006).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"8503_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005343.pub5","author":"SL Coleridge","year":"2019","unstructured":"Coleridge, S. L., Bryant, A., Kehoe, S. & Morrison, J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD005343.pub5 (2019).","journal-title":"Cochrane Database Syst. Rev."},{"key":"8503_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman, M. A. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27, 1419\u20131425. https:\/\/doi.org\/10.1200\/JCO.2008.19.1684 (2009).","journal-title":"J. Clin. Oncol."},{"key":"8503_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ygyno.2018.05.020","volume":"150","author":"K Lindemann","year":"2018","unstructured":"Lindemann, K. et al. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol. Oncol. 150, 239\u2013246. https:\/\/doi.org\/10.1016\/j.ygyno.2018.05.020 (2018).","journal-title":"Gynecol. Oncol."},{"key":"8503_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","volume":"133","author":"A Davis","year":"2014","unstructured":"Davis, A., Tinker, A. V. & Friedlander, M. \u201cPlatinum resistant\u201d ovarian cancer: What is it, who to treat and how to measure benefit? Gynecol. Oncol. 133, 624\u2013631. https:\/\/doi.org\/10.1016\/j.ygyno.2014.02.038 (2014).","journal-title":"Gynecol. Oncol."},{"key":"8503_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1530\/ERC-17-0336","volume":"25","author":"B van Zyl","year":"2018","unstructured":"van Zyl, B., Tang, D. & Bowden, N. A. Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment. Endocr. Relat. Cancer 25, 303\u2013318. https:\/\/doi.org\/10.1530\/ERC-17-0336 (2018).","journal-title":"Endocr. Relat. Cancer"},{"key":"8503_CR7","doi-asserted-by":"publisher","first-page":"11491","DOI":"10.1021\/acs.analchem.7b02746","volume":"89","author":"M Corte Rodr\u00edguez","year":"2017","unstructured":"Corte Rodr\u00edguez, M., \u00c1lvarez-Fern\u00e1ndez Garc\u00eda, R., Blanco, E., Bettmer, J. & Montes-Bay\u00f3n, M. Quantitative evaluation of cisplatin uptake in sensitive and resistant individual cells by single-cell ICP-MS (SC-ICP-MS). Anal. Chem. 89, 11491\u201311497. https:\/\/doi.org\/10.1021\/acs.analchem.7b02746 (2017).","journal-title":"Anal. Chem."},{"key":"8503_CR8","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1200\/JCO.2011.40.8120","volume":"30","author":"ES Kim","year":"2012","unstructured":"Kim, E. S. et al. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J. Clin. Oncol. 30, 3345\u20133352. https:\/\/doi.org\/10.1200\/JCO.2011.40.8120 (2012).","journal-title":"J. Clin. Oncol."},{"key":"8503_CR9","first-page":"6559","volume":"62","author":"K Katano","year":"2002","unstructured":"Katano, K. et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res. 62, 6559\u20136565 (2002).","journal-title":"Cancer Res."},{"key":"8503_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.lungcan.2014.04.005","volume":"85","author":"ES Kim","year":"2014","unstructured":"Kim, E. S. et al. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer 85, 88\u201393. https:\/\/doi.org\/10.1016\/j.lungcan.2014.04.005 (2014).","journal-title":"Lung Cancer"},{"key":"8503_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.03.019","author":"H Xu","year":"2021","unstructured":"Xu, H. et al. Intranasal levels of lead as an exacerbation factor for allergic rhinitis in humans and mice. J. Allergy Clin. Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2021.03.019 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"8503_CR12","doi-asserted-by":"publisher","first-page":"9854","DOI":"10.1038\/s41598-019-46056-4","volume":"2019","author":"MHM Ali","year":"2019","unstructured":"Ali, M. H. M., Rakib, F., Al-Saad, K., Al-Saady, R. & Goormaghtigh, E. An innovative platform merging elemental analysis and FTIR imaging for breast tissue analysis. Sci. Rep. 2019(9), 9854. https:\/\/doi.org\/10.1038\/s41598-019-46056-4 (2019).","journal-title":"Sci. Rep."},{"key":"8503_CR13","doi-asserted-by":"publisher","first-page":"40169","DOI":"10.1038\/srep40169","volume":"7","author":"J Anyz","year":"2017","unstructured":"Anyz, J. et al. Spatial mapping of metals in tissue-sections using combination of mass-spectrometry and histology through image registration. Sci. Rep. 7, 40169. https:\/\/doi.org\/10.1038\/srep40169 (2017).","journal-title":"Sci. Rep."},{"key":"8503_CR14","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1039\/C5MT00028A","volume":"7","author":"S Theiner","year":"2015","unstructured":"Theiner, S. et al. Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents. Metallomics 7, 1256\u20131264. https:\/\/doi.org\/10.1039\/C5MT00028A (2015).","journal-title":"Metallomics"},{"key":"8503_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aca.2014.04.048","volume":"835","author":"J Sabine Becker","year":"2014","unstructured":"Sabine Becker, J., Matusch, A. & Wu, B. Bioimaging mass spectrometry of trace elements\u2014Recent advance and applications of LA-ICP-MS: A review. Anal. Chim. Acta 835, 1\u201318. https:\/\/doi.org\/10.1016\/j.aca.2014.04.048 (2014).","journal-title":"Anal. Chim. Acta"},{"key":"8503_CR16","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1039\/c4mt00131a","volume":"6","author":"J Bianga","year":"2014","unstructured":"Bianga, J. et al. Complementarity of MALDI and LA ICP mass spectrometry for platinum anticancer imaging in human tumor. Metallomics 6, 1382\u20131386. https:\/\/doi.org\/10.1039\/c4mt00131a (2014).","journal-title":"Metallomics"},{"key":"8503_CR17","doi-asserted-by":"publisher","first-page":"A0065","DOI":"10.5702\/massspectrometry.A0065","volume":"7","author":"T Suzuki","year":"2018","unstructured":"Suzuki, T. et al. iQuant2: Software for rapid and quantitative imaging using laser ablation-ICP mass spectrometry. Mass Spectrom (Tokyo) 7, A0065. https:\/\/doi.org\/10.5702\/massspectrometry.A0065 (2018).","journal-title":"Mass Spectrom (Tokyo)"},{"key":"8503_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/s1470-2045(02)00847-1","volume":"3","author":"M Harries","year":"2002","unstructured":"Harries, M. & Gore, M. Part II: Chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 3, 537\u2013545. https:\/\/doi.org\/10.1016\/s1470-2045(02)00847-1 (2002).","journal-title":"Lancet Oncol."},{"key":"8503_CR19","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/cas.13599","volume":"109","author":"S Sun","year":"2018","unstructured":"Sun, S. et al. Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation. Cancer Sci. 109, 1853\u20131864. https:\/\/doi.org\/10.1111\/cas.13599 (2018).","journal-title":"Cancer Sci."},{"key":"8503_CR20","doi-asserted-by":"publisher","first-page":"16036","DOI":"10.18632\/oncotarget.13917","volume":"8","author":"S Sun","year":"2017","unstructured":"Sun, S., Cai, J., Yang, Q., Zhao, S. & Wang, Z. The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: A meta-analysis of literatures and datasets. Oncotarget 8, 16036\u201316051. https:\/\/doi.org\/10.18632\/oncotarget.13917 (2017).","journal-title":"Oncotarget"},{"key":"8503_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200038010-00001","volume":"38","author":"F L\u00e9vi","year":"2000","unstructured":"L\u00e9vi, F., Metzger, G., Massari, C. & Milano, G. Oxaliplatin: Pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. 38, 1\u201321. https:\/\/doi.org\/10.2165\/00003088-200038010-00001 (2000).","journal-title":"Clin. Pharmacokinet."},{"key":"8503_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF00262732","volume":"21","author":"ZH Siddik","year":"1988","unstructured":"Siddik, Z. H., Jones, M., Boxall, F. E. & Harrap, K. R. Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother. Pharmacol. 21, 19\u201324. https:\/\/doi.org\/10.1007\/BF00262732 (1988).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"8503_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s002800050024","volume":"45","author":"C Massari","year":"2000","unstructured":"Massari, C. et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother. Pharmacol. 45, 157\u2013164. https:\/\/doi.org\/10.1007\/s002800050024 (2000).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"8503_CR24","first-page":"761","volume":"5","author":"W Kern","year":"1999","unstructured":"Kern, W. et al. Oxaliplatin pharmacokinetics during a four-hour infusion. Clin. Cancer Res. 5, 761\u2013764 (1999).","journal-title":"Clin. Cancer Res."},{"key":"8503_CR25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00280-015-2823-7","volume":"76","author":"J-X Yin","year":"2015","unstructured":"Yin, J.-X., Wei, Z., Xu, J.-J. & Sun, Z.-Q. In vivo pharmacokinetic and tissue distribution investigation of sustained-release cisplatin implants in the normal esophageal submucosa of 12 beagle dogs. Cancer Chemother. Pharmacol. 76, 525\u2013536. https:\/\/doi.org\/10.1007\/s00280-015-2823-7 (2015).","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08503-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08503-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T19:46:30Z","timestamp":1669319190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-08503-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8503"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-08503-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-882249\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"7 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4513"}}